Cerity Partners LLC Acquires 165,556 Shares of GSK plc (NYSE:GSK)

Cerity Partners LLC increased its holdings in GSK plc (NYSE:GSK - Free Report) by 61.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 433,628 shares of the pharmaceutical company's stock after purchasing an additional 165,556 shares during the quarter. Cerity Partners LLC's holdings in GSK were worth $17,728,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. 1832 Asset Management L.P. lifted its position in shares of GSK by 9.1% in the 1st quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company's stock worth $132,000 after purchasing an additional 257 shares during the period. Boltwood Capital Management lifted its holdings in GSK by 2.5% in the second quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company's stock worth $429,000 after buying an additional 270 shares during the period. First Affirmative Financial Network boosted its position in GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company's stock valued at $245,000 after acquiring an additional 283 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of GSK by 9.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company's stock worth $137,000 after acquiring an additional 303 shares during the period. Finally, Mesirow Financial Investment Management Inc. raised its position in shares of GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company's stock worth $682,000 after acquiring an additional 323 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on GSK shares. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Barclays raised GSK to a "hold" rating in a research report on Tuesday, August 27th. Argus upgraded GSK to a "strong-buy" rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and reduced their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $43.25.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the company's stock in a transaction that occurred on Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.00% of the company's stock.

GSK Stock Performance

GSK traded down $0.21 during midday trading on Tuesday, hitting $33.94. 3,025,820 shares of the company traded hands, compared to its average volume of 4,152,950. The company's 50-day moving average is $37.90 and its 200 day moving average is $40.25. GSK plc has a 52 week low of $32.83 and a 52 week high of $45.92. The firm has a market capitalization of $70.34 billion, a PE ratio of 22.18, a price-to-earnings-growth ratio of 1.30 and a beta of 0.66. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.63%. The ex-dividend date is Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's payout ratio is 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.